Fulgent Genetics (FLGT) Operating Income (2015 - 2026)

Fulgent Genetics has disclosed Operating Income across 12 years of filings, most recently posting -$36.1 million for Q2 2026.

• In Q2 2026, Operating Income fell 82.99% year-over-year to -$36.1 million; the TTM figure through Jun 2026 stood at -$86.5 million (down 19.01% YoY), while the FY2025 annual figure was -$91.1 million, down 23.24% from the prior year.
• Operating Income came in at -$36.1 million for Q2 2026 at Fulgent Genetics, down from -$34.6 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $201.9 million in Q1 2022 to a low of -$151.1 million in Q4 2023.
• Average Operating Income over 5 years is -$12.1 million, with a median of -$19.3 million recorded in 2024.
• Year-over-year, Operating Income plunged 8080.84% in 2024 and surged 96.9% in 2025.
• Over 5 years, Operating Income stood at -$36.6 million in 2022, then plunged by 313.44% to -$151.1 million in 2023, then soared by 89.32% to -$16.1 million in 2024, then surged by 96.9% to -$500000.0 in 2025, then tumbled by 7114.6% to -$36.1 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$36.1 million in Q2 2026, -$34.6 million in Q1 2026, and -$500000.0 in Q4 2025.